Unique ID issued by UMIN | UMIN000027239 |
---|---|
Receipt number | R000025608 |
Scientific Title | Randomized controlled trial of covered metallic stent for malignant lower biliary stricture: Braded vs Laser-cut type |
Date of disclosure of the study information | 2017/05/03 |
Last modified on | 2022/11/07 19:21:01 |
Randomized controlled trial of covered metallic stent for malignant lower biliary stricture: Braded vs Laser-cut type
RCT of covered SEMS for MBS: Braded vs Laser-cut type
Randomized controlled trial of covered metallic stent for malignant lower biliary stricture: Braded vs Laser-cut type
RCT of covered SEMS for MBS: Braded vs Laser-cut type
Japan |
unresected malignancies causing lower or middle biliary stricture
Hepato-biliary-pancreatic medicine |
Malignancy
NO
Many have reported the utility of endoscopic treatment using self-expanded metallic stent (SEMS) for lower or middle biliary stricture caused by malignancies.
There are two types in SEMS, Braded and Laser-cut type, and they have each different feature. In the present study, we will prospectively compare and estimate the clinical outcomes between the two types of SEMS.
Safety,Efficacy
Confirmatory
rate of stent dysfunction one year after stent intervention
safety, success rate, time of stent patency, overall time of survival
Interventional
Parallel
Randomized
Individual
Single blind -participants are blinded
Active
YES
YES
2
Treatment
Device,equipment |
Intervention: Laser-cut type of SEMS
Control: Braded type of SEMS
20 | years-old | <= |
Not applicable |
Male and Female
1) Patients' age of more than 20 years-old.
2) Patients having lower or middle biliary stricture caused by unresectable malignancies
3) Patients having dilation of bile duct and cholangitis, obstructive jaundice or liver dysfunction.
4) Patients who are judged appropriate for endoscopic biliary stenting using metallic stent by chief (responsive) medical examiner.
5) Written informed consent is obtained from patient before the study.
1) Patients' age of less than 20 years-old.
2) Patients having resectable malignancies.
3) Written informed consent is not obtained from patient before the study.
4) Patients who are judged inappropriate by chief (responsive) medical examiner.
60
1st name | Takamitsu |
Middle name | |
Last name | Sato |
Yokohama City University School of Medicine
Department of Gastroenterology and Hepatology
236-0004
3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
+81-45-787-2640
tkmtsato@yokohama-cu.ac.jp
1st name | Takamitsu |
Middle name | |
Last name | Sato |
Yokohama City University School of Medicine
Department of Gastroenterology and Hepatology
236-0004
3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
+81-45-787-2640
tkmtsato@yokohama-cu.ac.jp
Yokohama city university Hospital
self funding
Self funding
Yokohama CIty University
1-1-1 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
+81-45-370-7629
rinri@yokohama-cu.ac.jp
NO
2017 | Year | 05 | Month | 03 | Day |
Unpublished
Enrolling by invitation
2016 | Year | 06 | Month | 01 | Day |
2016 | Year | 04 | Month | 30 | Day |
2016 | Year | 06 | Month | 01 | Day |
2023 | Year | 04 | Month | 30 | Day |
2017 | Year | 05 | Month | 03 | Day |
2022 | Year | 11 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025608